New drug BNT329 targets Hard-to-Treat cancers in early trial
NCT ID NCT07186842
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The drug works by targeting cancer cells and may help control tumor growth, but it is not expected to be a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE ESOPHAGOGASTRIC JUNCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Austin Health
RECRUITINGHeidelberg, 3084, Australia
-
Florida Cancer Specialists
RECRUITINGOrlando, Florida, 32827, United States
-
Hospital San Pedro
RECRUITINGLogroño, 26006, Spain
-
Hospital Universitari Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario HM Sanchinarro - START Madrid CIOCC
RECRUITINGMadrid, 28050, Spain
-
Hospital Universitario Quironsalud Madrid - NEXT Oncology
RECRUITINGPozuelo de Alarcón, 28223, Spain
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Monash Health
RECRUITINGClayton, 3168, Australia
-
Northern Centre for Cancer Research
RECRUITINGNewcastle upon Tyne, NE7 7DN, United Kingdom
-
Royal Free Hospital
RECRUITINGLondon, NW3 2QG, United Kingdom
-
SCRI at HCA Health One
RECRUITINGDenver, Colorado, 80218, United States
-
St James´s University Hospital
RECRUITINGLeeds, LS9 7TF, United Kingdom
-
St. Josef-Hospital im Katholischen Klinikum Bochum
RECRUITINGBochum, 44791, Germany
-
The Christie NHS Foundation Trust
RECRUITINGManchester, M20 4BX, United Kingdom
-
The Royal Marsden Hospital
RECRUITINGSutton, SM2 5PT, United Kingdom
-
Universitaetsklinikum Ulm
RECRUITINGUlm, D-89081, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Metabolic clues: could your Body's energy use predict ovarian cancer outcomes?
- Blood and gut clues may flag pancreatic cancer risk early
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?